RUBY-FILL is intended for use in cardiac PET imaging under rest or pharmacologic stress conditions. Credit: moxumbic / Shutterstock.com.

Jubilant DraxImage (Jubilant Radiopharma) has secured approval from the US Food and Drug Administration (FDA) for its RUBY Rubidium Elution System and Rubidium Rb82 generator (RUBY-FILL) to be used in mobile settings.

RUBY-FILL is intended for use in cardiac PET imaging under rest or pharmacologic stress conditions for assessing regional myocardial perfusion in patients with suspected or existing coronary artery disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest approval allows the company to expand cardiac PET use into smaller community hospitals, rural settings and areas where a full-time programme for cardiac PET is not available.

RUBY-FILL is a closed system designed to produce rubidium chloride injection for intravenous use.

The radioactive diagnostic agent Rubidium chloride injection is developed for positron emission tomography (PET) imaging of the myocardium.

Jubilant Radiopharma radiopharmaceuticals division president Sergio Calvo said: “The approval for mobile use with RUBY-FILL for cardiac PET is another example of Jubilant Radiopharma’s ongoing commitment to expand this imaging modality and increase patient access to this crucial test.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jubilant Radiopharma partnered with healthcare providers throughout the US to establish and expand cardiac PET programmes after FDA approval in 2016.

Meanwhile, Jubilant Radiopharma collaborated with Evergreen Theragnostics for the preparation, sale and distribution of OCTEVY (Kit for Preparation of Ga 68 DOTATOC Injection) to customers throughout the US.

Currently, OCTEVY is under assessment by the FDA as a potential radioactive diagnostic agent for use with PET to localise somatostatin receptor-positive neuroendocrine tumours in paediatric and adult patients.